Overview

  • Product name

    Human PARK7 ELISA Kit
    See all PARK7/DJ1 kits
  • Detection method

    Colorimetric
  • Precision

    Intra-assay
    Sample n Mean SD CV%
    Serum 8 7.3%
    Inter-assay
    Sample n Mean SD CV%
    Serum 3 5.7%
  • Sample type

    Cell culture supernatant, Urine, Serum, Cell culture extracts, Tissue Extracts, Heparin Plasma, EDTA Plasma, Citrate Plasma, Cerebral Spinal Fluid
  • Assay type

    Sandwich (quantitative)
  • Sensitivity

    147.4 pg/ml
  • Range

    0.781 ng/ml - 50 ng/ml
  • Recovery

    Sample specific recovery
    Sample type Average % Range
    Cell culture supernatant 102 98% - 106%
    Urine 94 92% - 96%
    Serum 106 97% - 116%
    Cell culture extracts 112 107% - 116%
    Tissue Extracts 86 84% - 89%
    Heparin Plasma 103 101% - 104%
    EDTA Plasma 121 119% - 124%
    Citrate Plasma 111 102% - 118%
    Cerebral Spinal Fluid 110 104% - 114%

  • Assay time

    1h 30m
  • Assay duration

    One step assay
  • Species reactivity

    Reacts with: Human
    Does not react with: Rat
  • Product overview

    PARK7 in vitro SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of PARK7 protein in human serum, plasma, cell culture supernatant, urine, cerebrospinal fluid, cell and tissue extracts.


    The SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.


    Sensitivity:
    Samples in Sample Diluent NS: 147.4 pg/mL
    Samples in 1X Cell Extraction Buffer PTR: 255.7 pg/mL

  • Notes

    PARK7 (also known as Protein deglycase DJ- or Parkinson disease protein 7) is member of the peptidase C56 family. PARK7 functions as a redox-sensitive chaperone and sensor for oxidative stress. It is also involved in the regulation of androgen receptor dependent transcription.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform

    Pre-coated microplate (12 x 8 well strips)

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 1 x 96 tests
    10X Human PARK7 Capture Antibody 1 x 600µl
    10X Human PARK7 Detector Antibody 1 x 600µl
    10X Wash Buffer PT (ab206977) 1 x 20ml
    50X Cell Extraction Enhancer Solution (ab193971) 1 x 1ml
    5X Cell Extraction Buffer PTR (ab193970) 1 x 10ml
    Antibody Diluent 5BI 1 x 6ml
    Human PARK7 Lyophilized Recombinant Protein 2 vials
    Plate Seals 1 unit
    Sample Diluent NS (ab193972) 1 x 50ml
    SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit
    Stop Solution 1 x 12ml
    TMB Development Solution 1 x 12ml
  • Research areas

  • Function

    Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone.
  • Tissue specificity

    Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa.
  • Involvement in disease

    Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).
  • Sequence similarities

    Belongs to the peptidase C56 family.
  • Post-translational
    modifications

    Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
    Cys-106 is easily oxidized to sulfinic acid.
    Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.
  • Cellular localization

    Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients.
  • Information by UniProt
  • Alternative names

    • CAP1
    • DJ-1
    • DJ1
    • DJ1 protein
    • Epididymis secretory sperm binding protein Li 67p
    • FLJ27376
    • FLJ34360
    • FLJ92274
    • HEL S 67p
    • Oncogene DJ1
    • OTTHUMP00000001348
    • OTTHUMP00000001349
    • OTTHUMP00000001350
    • OTTHUMP00000001351
    • PARK7
    • PARK7_HUMAN
    • Parkinson disease (autosomal recessive, early onset) 7
    • Parkinson disease protein 7
    • Parkinson protein 7
    • Protein DJ-1
    • SP22
    see all
  • Database links

Applications

Our Abpromise guarantee covers the use of ab215535 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Images

  • SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.

     

  • Background-subtracted data values (mean +/- SD) are graphed.

  • Background-subtracted data values (mean +/- SD) are graphed.

  • The concentrations of PARK7 were measured in duplicates, interpolated from the PARK7 standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 25%, plasma (citrate) 25%, plasma (heparin) 25% and plasma (EDTA) 25%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PARK7 concentration was determined to be 87.44 ng/mL in serum, 85.56 ng/mL in plasma (citrate) and 68.65 ng/mL in plasma (heparin) and 86.19 ng/mL in plasma (EDTA).

  • The concentrations of PARK7 were measured in duplicate and interpolated from the PARK7 standard curve and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PARK7 concentration was determined to be 18.17 ng/mL in fetal brain extract and 34.57 ng/mL in HL-60 extract.

  • Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PARK7 concentration was determined to be 82.40 ng/mL with a range of 7.39 – 216.70 ng/mL

  • Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PARK7 concentration was determined to be 64.23 ng/mL with a range of 7.85 – 235.44 ng/mL.

  • Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PARK7 concentration was determined to be 10.76 ng/mL with a range of 2.93 – 30.74 ng/mL.

Protocols

References

ab215535 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab215535.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up